Accueil   Diary - News   All news Valneva announces the launch of a capital increase

Valneva announces the launch of a capital increase

Following its announcement on January 5th, European biotechnology company Valneva announced the launch of a capital increase with preferential subscription rights for holders of ordinary shares for a gross amount of approximately EUR 45 million (the “Rights Issue”). This Rights Issue is part of the financing for the acquisition of Crucell Sweden AB and all assets, licenses and privileges related to Dukoral®1, a vaccine against cholera and traveler’s diarrhea caused by ETEC (Enterotoxigenic Escherichia coli), as well as a Nordics vaccine  distribution business of the seller and its affiliates (the “Acquisition”). The net proceeds of the Rights Issue are estimated to amount to approximately EUR 42 million.

 

Read the press release

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree